Insider · CIK 0001883722
Julie Burgess
Files at DSGN (Design Therapeutics, Inc.). First filing -, latest -.
Julie Burgess files SEC Form 4 as officer at DSGN (Design Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Julie Burgess has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | DSGN Design Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Jan 5, 2026 |
| Jan 2, 2025 | DSGN Design Therapeutics, Inc. | AGrant or award Stock option (right to buy)derivative | +135,000 | $0.00 | $0 | 135,000 | Jan 6, 2025 |
Questions about Julie Burgess
Answered from the filings on this page, as of the latest one.
Is Julie Burgess buying or selling?
Julie Burgess has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Julie Burgess's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Julie Burgess has 0.
Where does Julie Burgess file Form 4?
Julie Burgess has filed Form 4 at DSGN (Design Therapeutics, Inc.) as Chief Accounting Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.